Why Is 10X GENOMICS INC A (TXG) Stock Down Today?

10X Genomics Inc A (TXG) fell 6.82% to $75.16 on October 7, 2026, marking a significant decline amid mixed news. The stock opened with a 1.0% gap down and continued to trend lower throughout the session, reaching an intraday low of $73.00. The move coincided with the announcement of a new multi-project research collaboration with Fred Hutchinson Cancer Center, which did not immediately buoy investor sentiment.

What Happened

The company announced a research collaboration with Fred Hutchinson Cancer Center to apply single cell and spatial technologies in the study of bladder cancer and acute myeloid leukemia. The collaboration aims to advance biomarker discovery and residual disease detection. This development was reported by multiple outlets, including MarketChameleon and PR Newswire. However, the stock price continued to fall, closing the session at $75.16. Earlier in the week, the stock had dropped 13.4%, and a price target increase from $52 to $110 at Barclays did not appear to offset the downward pressure.

What The Data Shows

TXG has been volatile in recent months, trading within a 52-week range of $11.16 to $102.81. The stock has lost 3.5% over the past eight sessions, moving from $85.71 to $82.67. On October 7, it printed five fresh 52-week lows. The intraday volume of 1.4 million shares was 0.4 times the 3-month average, suggesting limited liquidity. Additionally, insiders including the CEO and CFO sold shares in recent weeks, with total insider sales over 90 days reaching $12.2 million.

What To Watch

Investors should monitor the company’s upcoming earnings report if scheduled, as well as any further analyst coverage or updates from the Fred Hutchinson collaboration. The stock remains unprofitable with a net margin of -12.2% and declining revenue, which may continue to influence its trajectory.